NCT05712902进行中（未招募）2 期
A Phase II, Single Arm, Multicenter Study to Evaluate Anti-tumor Activity, Safety, Tolerability and Pharmacokinetics of DZD9008 in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutation
Dizal Pharmaceuticals33 个研究点 分布在 1 个国家目标入组 104 人开始时间: 2021年7月19日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 104
- 试验地点
- 33
- 主要终点
- Objective Response Rate (ORR) according to RECIST 1.1 by an Independent Review Committee (IRC)
研究概览
简要总结
This is a Phase II, single-arm, multi-center clinical study to evaluate the anti-tumor efficacy, safety, tolerability and pharmacokinetics of Sunvozertinib in participants with locally advanced or metastatic NSCLC carrying EGFR exon 20 insertion mutations whose disease has progressed on prior platinum-based chemotherapy
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must be able to understand the nature of the trial and provide a signed and dated, written informed consent form.
- •Aged at least 18 years old.
- •Histological or cytological confirmed locally advanced or metastatic NSCLC
- •Tumor tissue EGFR exon 20 insertion mutations confirmed by qualified local laboratories or sponsor-designated central laboratories.
- •Participants must exhibit Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1 at ICF signature with no deterioration over the past 2 weeks.
- •Predicted life expectancy ≥ 12 weeks.
- •Patient must have measurable disease according to RECIST 1.
- •Patients with brain metastasis (BM) can only be enrolled under the condition that BM is previously treated and stable.
- •Adequate organ system functions.
- •Patients should receive at least one line but no more than three lines of prior systemic therapy (at least one line must contain platinum-based therapy).
排除标准
- •Prior malignancy within 2 years requires active treatment, except for adequately treated basal cell skin carcinoma, in situ cervical carcinoma, or other cancer types (to be discussed with Dizal's Study Physician) who has been disease free for > 2 years with life expectancy >2 years.
- •Any unresolved toxicities from prior therapy greater than CTCAE grade 1 at the time of starting Sunvozertinib with the exception of alopecia and grade 2 prior platinum-therapy related neuropathy.
- •Spinal cord compression or leptomeningeal metastasis.
- •History of stroke or intracranial hemorrhage within 6 months before first administration of Sunvozertinib.
- •Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses.
- •Active infection including hepatitis B, hepatitis C, human immunodeficiency virus (HIV) and COVID-
- •Any of the following cardiac criteria:
- •Mean resting corrected QT interval (QTc) > 470 msec obtained from 3 electrocardiograms (ECGs).
- •Any clinically significant abnormalities in rhythm, conduction or morphology of resting ECG, e.g., complete left bundle branch block, third degree heart block, and second-degree heart block, PR interval > 250 msec.
- •Any factors that increase the risk of QTc prolongation, such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first degree relatives or any concomitant medication known to prolong the QT interval .
- •Prior history of atrial fibrillation within 6 months of first administration of Sunvozertinib, except prior drug treatment related and recovered.
- •Participants with hemorrhagic diseases such as von Willebrand disease.
- •Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease or immunotherapy induced immune pneumonia.
- •Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of Sunvozertinib.
- •Prior/concomitant therapy
- •Patients who have received prior Poziotinib, TAK-788, CLN-081 or BDTX-189, furmonertinib or any other EGFR/HER2 exon20ins small molecule inhibitors treatment should be excluded.
- •Other EGFR TKIs, such as gefitinib, erlotinib, osimertinib, afatinib, dacomitinb are not considered EGFR or HER2 Exon20ins small molecule inhibitors, and thus prior treatment with these drugs is allowed unless the patient had an objective response and subsequent progression as assessed by the investigator or treating physician during treatment with that prior TKI.
- •Treatment with antibodies within 4 weeks before first administration of Sunvozertinib.
- •Any cytotoxic chemotherapy, investigational agents or other anticancer drugs from a previous treatment regimen or clinical study within 14 days before first administration of Sunvozertinib.
- •Women who are pregnant or breast feeding.
研究组 & 干预措施
Daily dose of Sunvozertinib
Experimental
干预措施: Sunvozertinib (Drug)
结局指标
主要结局
Objective Response Rate (ORR) according to RECIST 1.1 by an Independent Review Committee (IRC)
时间窗: From first dosing until disease progression or intolerable adverse events
次要结局
未报告次要终点
研究者
研究点 (33)
Loading locations...
相似试验
终止
2 期
NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLCCarcinoma, Non-Small-Cell LungNon-Small Cell Lung CarcinomaNonsmall Cell Lung CancerNon Small Cell Lung CancerNon-Small Cell Lung CancerNCT04984811NeoImmuneTech33
已完成
2 期
A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal CarcinomaNasopharyngeal CarcinomaNCT04220307Akeso34
尚未招募
2 期
A Single-arm, Single-center Phase II Clinical Study on the Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection Combined With Fruquintinib Capsules in the Second-line Treatment of Patients With Advanced Gastric CancerAdvanced Gastric CancerPaclitaxel Polymeric Micelles for InjectionFruquintinib CapsulesNCT06706895Shanghai Zhongshan Hospital21
已完成
2 期
A Study of Anti-PD-1 AK105 in Patients With Metastatic Nasopharyngeal CarcinomaNasopharyngeal CarcinomaNCT03866967Akeso130
招募中
2 期
Neoadjuvant Envafolimab Plus Disitamab Vedotin and Carboplatin in Resectable HER2-Mutant Non-Small-Cell Lung CancerNon-small Cell Lung CancerNCT06734182Guangdong Provincial People's Hospital25
相关资讯
FDA Filing Accepted for Sunvozertinib in EGFR Exon 20 Insertion-Positive NSCLC- Dizal's sunvozertinib NDA has been submitted to the FDA for treating NSCLC with EGFR exon 20 insertion mutations after platinum-based chemotherapy.
- The NDA submission is backed by phase 2 WU-KONG1 trial data, which demonstrated a 53.3% overall response rate in patients treated with sunvozertinib.
- The median duration of response was not reached, with a 9-month duration of response rate of 57% observed in the study.
- Sunvozertinib has already been approved in China for similar indications, marking Dizal's first NDA submission to the FDA.last yearSunvozertinib NDA Submitted to FDA for EGFR Exon 20+ NSCLC- Dizal has submitted an NDA to the FDA for sunvozertinib to treat NSCLC with EGFR exon 20 insertion mutations after platinum-based chemotherapy.
- The NDA submission is based on the phase 2 WU-KONG1 trial, which showed a 44.9% confirmed ORR in patients treated with sunvozertinib at 300 mg.
- The median duration of response was not reached, with a 9-month DOR rate of 57% in the sunvozertinib arm.
- Sunvozertinib has already been approved in China for the same indication based on the WU-KONG6 trial data.last year